Views

CrossRef citations to date

Altmetric

Original Articles: Clinical

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

José FalantesDepartment of Hematology, University Hospital Virgen del Rocío, Seville, Spain;

Lisa Pleyer3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Hospital Salzburg, Salzburg, Austria; ;Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; ;Cancer Cluster Salzburg, Salzburg, Austria;

Sylvain ThépotDepartment of Blood Diseases/Hematology, CHU Angers, Angers, France;

António M. AlmeidaDepartment of Hematology, Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal;

Luca MaurilloDepartment of Hematology, Tor Vergata Foundation Polyclinic, University of Rome, Rome, Italy;

Violeta Martínez-RoblesDepartment of Hematology, University Hospital, León, Spain;

Reinhard StauderDepartment of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria;

Raphael ItzyksonDepartment of Hematology, Saint Louis Hospital, Paris VII University (APHP), Paris, France;

Ricardo PintoDepartment of Hematology, Hospital São João, Porto, Portugal;

Adriano VendittiDepartment of Hematology, Tor Vergata Foundation Polyclinic, University of Rome, Rome, Italy;

Joan BargayDepartment of Hematology, Son Llatzer Hospital, Palma de Mallorca, Spain;

Sonja BurgstallerDepartment of Internal Medicine IV, Wels-Grieskirchen Hospital, Wels, Austria;

María Pilar MartínezDepartment of Hematology, Doce de Octubre University Hospital, Madrid, Spain;

Valerie SeegersDepartment of Hematology, Avicenne Hospital, Paris XIII University (APHP), Bobigny, France;

Emilia CortesãoDepartment of Hematology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal;

María Ángeles FoncillasDepartment of Hematology, Infanta Leonor University Hospital, Madrid, Spain;

Claude GardinDepartment of Hematology, Avicenne Hospital, Paris XIII University (APHP), Bobigny, France;

Pau MontesinosDepartment of Hematology, La Fe University Hospital, Valencia, Spain;

Pellegrino MustoScientific Direction, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy;

Pierre FenauxDepartment of Hematology, Saint Louis Hospital, Paris VII University (APHP), Paris, France;

Richard Greil3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Hospital Salzburg, Salzburg, Austria; ;Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; ;Cancer Cluster Salzburg, Salzburg, Austria;

Miguel Angel SanzDepartment of Hematology, La Fe University Hospital, Valencia, Spain;

Fernando RamosDepartment of Hematology, University Hospital, León, Spain; ;Institute of Biomedicine, University of León, León, SpainCorrespondence[email protected]

& for the European ALMA + Investigators show all

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Supplemental Figure 2

Supplemental Figure 1

Supplemental Table 1

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Supplemental Figure 2

Supplemental Figure 1

Supplemental Table 1

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date